- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure
September 10th 2024, 10:20pm
IASLC World Conference on Lung Cancer
Taletrectinib was safe and generated durable responses in both TKI-naive and -pretreated patients with ROS1-positive non–small cell lung cancer.
Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC
September 10th 2024, 7:24pm
IASLC World Conference on Lung Cancer
Neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab improves event-free survival in stage IIA-IIIB resectable non–small cell lung cancer vs. placebo.
Dr Le on SOHO-01 Data With BAY 2927088 in HER2-Mutated NSCLC
September 10th 2024, 6:49pm
IASLC World Conference on Lung Cancer
Xiuning Le, MD, PhD, discusses updated findings from the phase 1/2 SOHO-01 trial.
Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC
September 10th 2024, 6:45pm
IASLC World Conference on Lung Cancer
The safety profile of adjuvant alectinib was tolerable and manageable in ALK-positive NSCLC.
Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC
September 10th 2024, 6:44pm
IASLC World Conference on Lung Cancer
Tarlatamab demonstrated durable responses and long-term tolerability in patients with previously treated small cell lung cancer.
Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status
September 10th 2024, 5:43pm
IASLC World Conference on Lung Cancer
Rilvegostomig induced responses with acceptable tolerability in patients with checkpoint inhibitor-naive, metastatic NSCLC.
Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLC
September 10th 2024, 5:20pm
IASLC World Conference on Lung Cancer
Natasha B. Leighl, MD, BSc, MMSc, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study.
Dr Heymach on Updated AEGEAN Data in Resectable NSCLC
September 9th 2024, 10:30pm
IASLC World Conference on Lung Cancer
John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.
Analysis Further Shows Perioperative Pembrolizumab Efficacy in Early-Stage NSCLC
September 9th 2024, 9:41pm
IASLC World Conference on Lung Cancer
Neoadjuvant pembrolizumab plus chemotherapy led to greater pathologic regression vs placebo plus chemotherapy in early-stage non–small cell lung cancer.
Osimertinib Plus Savolitinib Exhibits Clinically Meaningful ORR vs Osimertinib in EGFR+ NSCLC
September 9th 2024, 9:25pm
IASLC World Conference on Lung Cancer
The combination of osimertinib/savolitinib demonstrated a significant improvement in ORR in de novo MET-aberrant, EGFR-mutant advanced NSCLC.
Firmonertinib Shows Antitumor Activity in EGFR PACC-Mutated NSCLC
September 9th 2024, 9:20pm
IASLC World Conference on Lung Cancer
Treatment with firmonertinib was safe and effective for patients with EGFR P-loop and αC-helix compressing-mutated non–small cell lung cancer.
Aumolertinib Improves PFS in Unresectable, Stage III EGFR+ NSCLC after Chemoradiotherapy
September 9th 2024, 8:42pm
IASLC World Conference on Lung Cancer
Treatment with aumolertinib led to an improvement in progression-free survival in unresectable, stage III, EGFR-mutated non–small cell lung cancer.
Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL
September 9th 2024, 8:30pm
Society of Hematologic Oncology Annual Meeting (SOHO)
Zanubrutinib was associated with lower treatment switching rates vs acalabrutinib and ibrutinib in real-world chronic lymphocytic leukemia.
Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC
September 9th 2024, 7:06pm
IASLC World Conference on Lung Cancer
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.
BAY 2927088 Displays Durable Responses in HER2-Mutated NSCLC
September 9th 2024, 6:53pm
IASLC World Conference on Lung Cancer
BAY 2927088 demonstrated durable response rates for patients with pretreated HER2-mutant non–small cell lung cancer.
Sacituzumab Govitecan Generates Responses With Manageable Safety Profile in ES-SCLC
September 9th 2024, 6:47pm
IASLC World Conference on Lung Cancer
Treatment with sacituzumab govitecan in the second-line setting yielded antitumor activity in patients with extensive-stage small cell lung cancer.
Dr Wu on SAFFRON-301 Data in Advanced or Metastatic NSCLC
September 9th 2024, 6:21pm
IASLC World Conference on Lung Cancer
Yi-Long Wu, MD, PhD, discusses findings from the phase 3 SAFFRON-301 trial in patients with advanced or metastatic NSCLC.
Dato-DXd Misses OS End Point in TROPION-Lung01 Study for NSCLC
September 9th 2024, 6:00pm
IASLC World Conference on Lung Cancer
Dato-DXd did not significantly improve overall survival compared with docetaxel for patients with non–small cell lung cancer.
HS-20093 Generates Responses in Pretreated ES-SCLC
September 9th 2024, 5:00pm
IASLC World Conference on Lung Cancer
HS-20093 produced responses in extensive-stage small cell lung cancer after prior platinum-based chemotherapy with or without prior immunotherapy.
Frontline Amivantamab/Lazertinib Combo Shows Trend of OS Benefit in Advanced EGFR+ NSCLC
September 9th 2024, 2:08am
IASLC World Conference on Lung Cancer
When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.